SHIMADZU BIOTECH LAUNCHES
AXIMA-QIT?- THE LATEST IN MASS SPECTROMETRY
Unique instrument aimed at proteomics research
January 15, 2002 Shimadzu Biotech announces that it will launch a revolutionary new product, AXIMA-QIT? early in the New Year. AXIMA-QIT represents a significant development in MALDI-TOF mass spectrometry. The unique hybrid configuration has been specifically designed for proteomics and drug discovery research and development.
Using radically new technology for trapping ions, Shimadzu Biotech is confident that the AXIMA-QIT will have a profound influence on the way problems are solved in the development of therapeutics. Unprecedented levels of structural information for all biological molecules can be derived from AXIMA-QIT's MSn analysis and sequencing, with the highest degree of confidence. Until now, protein identification has relied upon 30% of sequence coverage. To understand the structural significance of target proteins in biological function or drug discovery, 100% of the sequence must be elucidated. AXIMA-QIT has been created with this aim in mind.
The unique characteristics of the AXIMA-QIT enable structural elucidation of peptides, carbohydrates and other biological samples, including de novo sequencing and quantitative determination of protein expression using ICAT -type reagents.
The instrument offers unparalleled performance, with high mass resolution across MS and MSn analysis, constant mass accuracy - independent of laser energy and sample surface topography, and a rapid analysis time for high-throughput. Novel features include: near perpendicular laser irradiation for high efficiency of ion generation and transfer to the quadrupole ion trap (QIT); time-of-flight resolution and wide mass range of ions trapped up to 20 kDa. Excellent tolerance to non-conductive target materials is afforded by the platform's very low acceleration voltage of below 100V, without compromising its sensitivity.
High-resolution parent ion selection and low and high-energy collision-induced dissociation are possible using the QIT instrumentation. Shimadzu-Biotech's powerful LAUNCHPAD? software package supports the unique functionality of the AXIMA-QIT including automated data dependent MS/MS analysis using INTELLIMARQUE?.
The instrument takes advantage of all the best aspects of mass spectrometry, offering superior functionality, particularly for the next generation of problem solving in proteomics.
2026年9月2-4日,日本東京實驗室分析儀器、科學儀器展覽會JASIS2026于日本千葉幕張展覽館盛大舉辦,匯聚全球儀器廠商,集中展示生命科學、醫藥、食品、環境等領域前沿分析技術與整體解決方案。展會......
宣布推出基于MALDI-TOFMS的下一代微生物鑒定平臺,該平臺擁有最廣泛的數據庫,涵蓋約85,000種原核生物,不僅包括眾所周知的、先前描述的微生物,......
材料研發邁入數智閉環時代!島津聯合中國科學院物理研究所EX11組,基于HMV-G31-FA全自動顯微維氏硬度計完美定制自動化方案,搭配外部機械臂聯動進出樣,補齊國內先進合金數智研發平臺高通量表征短板,......
當AI技術開始重構各個行業的生產方式,實驗室管理領域的智能化變革也終于到來。LabSolutionsBiX正式推出島津首款AI驅動的專屬實驗室管理助手——BiXBoT,以AI為中樞打通實驗室全量運行數......
2026年7月24-27日,“第24屆全國分子光譜學學術會議暨第六屆光譜年會”在山西省太原市召開。分子光譜會由中國光學學會、中國化學會、中國光學學會光譜專業委員會主辦,山西大學承辦。本屆延續歷屆光譜會......
近日,重慶交通大學國家級科研平臺設備更新項目-水利水運實驗設備更新項目發布了中標公告。總項目金額超637萬,其中島津的GCMS-TQ8050NX以138.6萬中標。詳情如下:一、項目號:CQS26A0......
7月10日,島津制作所宣布完成對GlassHoldCo有限責任公司全部股權的收購。該公司間接持有歐洲電子顯微領域龍頭企業泰斯肯集團(TESCANGROUP,a.s.,下稱“泰斯肯”)全部股份,收購價格......
——島津氣相色譜全球產品經理武知亮專訪2026年,恰逢島津氣相色譜誕生70周年。在第十一屆島津化工論壇現場,島津正式發布新一代旗艦級氣相色譜儀NexisGC-2060和硅微閥氣相色譜儀FluxEdge......
2025年,科學儀器行業走出了前兩年的低谷。26家頭部企業的財報顯示,總營收首次突破2100億美元,凈利潤率普遍回升。但在這張“修復”的成績單背后,企業之間的分化也在加劇——有的靠并購和整合實現躍升,......
2026年6月12日,生態環境部辦公廳發布環辦輻射函〔2026〕218號復函,正式批復同意對島津企業管理(中國)有限公司GC-2060型氣相色譜儀最終用戶的使用活動實行豁免管理。生態環境部關于同意對島......